Urine metabolomics study of intervention of Xihuang Pills in rats with hyperplasia of mammary gland.
10.19540/j.cnki.cjcmm.20230630.403
- Author:
Jing-Rui WANG
1
;
Rui TAO
1
;
Xue-Li MA
1
;
Jun-Liang WANG
1
;
Tao HAN
2
Author Information
1. College of Pharmacy, Gansu University of Chinese Medicine Lanzhou 730000, China.
2. College of Pharmacy, Gansu University of Chinese Medicine Lanzhou 730000, China Key Laboratory of Pharmacology and Toxicology of Traditional Chinese Medicine of Gansu Province Lanzhou 730000, China.
- Publication Type:Journal Article
- Keywords:
UPLC-Q-Orbitrap-MS;
Xihuang Pills;
hyperplasia of mammary gland;
urine metabolomics
- MeSH:
Humans;
Rats;
Animals;
Chromatography, High Pressure Liquid/methods*;
Hyperplasia;
Metabolomics/methods*;
Metabolome;
Biomarkers/urine*
- From:
China Journal of Chinese Materia Medica
2023;48(20):5632-5640
- CountryChina
- Language:Chinese
-
Abstract:
This study aimed to investigate the mechanism of Xihuang Pills in improving hyperplasia of mammary gland(HMG) in rats based on urine metabolomics using ultra-performance liquid chromatography-quadrupole-Orbitrap mass spectrometry(UPLC-Q-Orbitrap-MS). The HMG rat model was established by intramuscular injection of estradiol benzoate solution(0.5 mg·kg~(-1), 25 days) followed by progesterone injection(5 mg·kg~(-1), 5 days). UPLC-Q-Orbitrap-MS technology was used to establish the endogenous small-molecule metabolic profiles in urine samples of rats in the blank group, the HMG model group, and Xihuang Pills group. Multivariate statistical analysis was performed for pattern recognition, t test and variable importance in the projection(VIP) were used to screen potential biomarkers. The significantly changed differential metabolites were identified using the online database Human Metabolome Database(HMDB). Metabolic pathway enrichment analysis was conducted using the MetaboAnalyst 5.0 database. The results showed that 90 differential metabolites with significant changes(P<0.05) were identified between the blank group and the HMG model group using the HMDB. Among them, 48 metabolites significantly reverted(P<0.05) after administration of Xihuang Pills, which may be related to the regulatory effect of Xihuang Pills. Thirteen metabolic pathways significantly associated with HMG were identified when the differential metabolites were imported into the MetaboAnalyst 5.0 database, and Xihuang Pills could modulate seven of these pathways. These metabolic pathways mainly involved histidine metabolism, arginine and proline metabolism, β-alanine metabolism, glycine, serine and threonine metabolism, tryptophan metabolism, pyrimidine metabolism, and amino sugar and nucleotide sugar metabolism. This study utilized UPLC-Q-Orbitrap-MS and urine metabolomics technology to analyze the mechanism of Xihuang Pills in improving HMG, laying the foundation for further in-depth research.
